Compare GPK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPK | PCVX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 7.0B |
| IPO Year | 2007 | 2020 |
| Metric | GPK | PCVX |
|---|---|---|
| Price | $9.66 | $59.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $13.08 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 4.5M | 984.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,617,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.79 | $30.81 |
| 52 Week High | $20.44 | $65.00 |
| Indicator | GPK | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 30.70 | 49.74 |
| Support Level | $9.24 | $58.51 |
| Resistance Level | $10.02 | $63.39 |
| Average True Range (ATR) | 0.36 | 2.07 |
| MACD | -0.21 | -0.40 |
| Stochastic Oscillator | 9.21 | 23.29 |
Graphic Packaging Holding Co is a holding company that manufactures and sells a variety of paper-based consumer packaging products through its subsidiaries. The company's reportable segments are; Americas Paperboard Packaging, and International Paperboard Packaging. The majority of the revenue is generated from its Americas Paperboard Packaging segment which includes paperboard packaging sold predominantly to consumer packaged goods (CPG) companies and cups, lids and food containers sold to foodservice companies and quick-service restaurants (QSR) serving the food, beverage, and consumer product markets in the Americas. Geographically, the company operates in Americas, Europe and Asia Pacific regions.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.